In a study of more than 500 adults, Moderna’s BA.4/BA.5-targeted vaccine proved a “superior” response three months after inoculation, according to the Nov. 14 news release.
Pfizer has not indicated whether it is testing its modified booster for its effectiveness against BQ.1 and BQ.1.1, which currently account for 44.2 percent of U.S. cases, according to CDC data.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
